<DOC>
	<DOCNO>NCT01856465</DOCNO>
	<brief_summary>Non-alcoholic fatty liver disease ( NAFLD ) include benign hepatic simple steatosis ( SS ) steatohepatitis ( NASH ) , characterise inflammation lead fibrosis cirrhosis . NAFLD hepatic manifestation metabolic syndrome , prevalence 74-98 % morbidly obese individual undergo bariatric surgery . Although steatosis improve post bariatric surgery , hepatic inflammation fibrosis consistently improve . Alterations human gut flora ( intestinal microbiota ; IM ) may play role . One mechanism link IM obesity , insulin resistance ( IR ) , NAFLD translocation bacterial lipopolisaccharide ( LPS=endotoxin ) blood stream ( =endotoxemia ) , cause chronic inflammation . Morbidly obese subject different IM compare lean control , IM structure significantly alter bariatric surgery , probably due combination anatomic change , diet , weight loss . For example , ratio Firmicutes/Bacteroidetes may lower obese subject compare lean control low number Faecalibacterium prausnitzii report obese subject bariatric surgery , increase 3 month post-surgery . This interest since , animal study , low abundance F. prausnitzii , butyrate produce bacterium , associate increase intestinal permeability , endotoxemia , inflammation . To knowledge , two study available describe IM patient pre post bariatric surgery , data publish relationship IM NAFLD patient .</brief_summary>
	<brief_title>Intestinal Microbiota NAFLD Pre Post Bariatric Surgery</brief_title>
	<detailed_description>Study Design : A. Cross-sectional study : Sixty patient morbid obesity undergo bariatric surgery diagnose NAFLD liver biopsy ( 30 SS , 30 NASH ) . Main hypothesis : The ratio Firmicutes/Bacteroidetes high stool sample morbidly obese subject NASH compare SS . Other difference IM composition exist . Objective : compare bacterial dynamic use Illumina technology ass IM . The relative abundance dominant fecal microorganism ( include Firmicutes , Archaea , Bacteroides , Bifidobacteria , Mollicutes , Enterobacteriaceae , Clostridia cluster , F. prausnitzii , Roseburia , Lactobacilli ) also assess real-time PCR . Sub-hypotheses : In NASH compare SS , : ) low fecal butyrate concentration ; b ) high endotoxin inflammatory marker ( TNF-α , IL-6 ) plasma . Potential covariates assess : small intestinal bacterial overgrowth ( SIBO ) , measure glucose hydrogen breath test ( GHBT ) , contribute endotoxemia inflammation ; IR , diabetes status , lipid profile , plasma vitamin E , liver enzymes , anthropometry , food intake , physical activity environmental factor . B . Prospective cohort study : Patients undergo bariatric surgery either SS NASH ( 60 recruit Part A ) follow prospectively 12 month assess change IM liver histology . Goal 60 subject complete study 2nd liver biopsy . Main Hypothesis : In morbidly obese patient NAFLD ( SS NASH ) , change IM post bariatric surgery associate change liver histology . Specifically , increase number F. prausnitzii feces associate improvement liver histology reduction associate deterioration liver histology . Objective : To correlate change liver histology ( NAFLD activity score [ NAS ] , inflammation , fibrosis , steatosis ) 0 12 month change F. prausnitzii . Other change fecal IM community structure , fecal short chain fatty acid ( include butyrate ) , plasma endotoxin , inflammatory marker ( TNF-α , IL-6 ) SIBO also assess , addition diet , activity , weight change , improvement diabetes plasma vitamin E. Secondary hypothesis : Increased number F. prausnitzii feces associate increased fecal butyrate , low serum endotoxin lower inflammatory marker ( TNF-α , IL-6 ) plasma . Significance : In human morbid obesity NAFLD undergo bariatric surgery , little data available IM metabolic effect contribution NAFLD . These study add information regard role IM effect potential mechanism contribute NAFLD . It also provide u pilot data future intervention study assess potential use pre- probiotic NAFLD morbidly obese subject set bariatric surgery .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Obesity , Morbid</mesh_term>
	<criteria>BMI &gt; 40 kg/m2 BMI &gt; 3540 kg/m2 severe weight loss comorbidities Male female , equal 18 year age Alcohol consumption lea 20 g/d No diagnosis NAFLD Having liver disease etiology Having advance liver disease Having abnormal coagulation reason contraindicate Liver Biopsy On medication know precipitate steatohepatitis 6 month prior entry On regular intake nonsteroidal antiinflammatory drug , prebiotics , probiotic antibiotic , ursodeoxycholic experimental drug 3 month prior study entry Having type1 diabetes , chronic gastrointestinal disease , previous gastrointestinal surgery modify anatomy ( prior bariatric surgery ) Smoking Pregnancy Breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Bariatric surgery</keyword>
	<keyword>NAFLD</keyword>
	<keyword>Steatohepatitis</keyword>
	<keyword>Simple Steatosis</keyword>
	<keyword>Intestinal Microbiota</keyword>
</DOC>